<SEC-DOCUMENT>0001193125-20-229312.txt : 20200825
<SEC-HEADER>0001193125-20-229312.hdr.sgml : 20200825
<ACCEPTANCE-DATETIME>20200825092659
ACCESSION NUMBER:		0001193125-20-229312
CONFORMED SUBMISSION TYPE:	S-3ASR
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20200825
DATE AS OF CHANGE:		20200825
EFFECTIVENESS DATE:		20200825

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACADIA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001070494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				061376651
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3ASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-248401
		FILM NUMBER:		201129692

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-558-2871

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3ASR
<SEQUENCE>1
<FILENAME>d18921ds3asr.htm
<DESCRIPTION>S-3ASR
<TEXT>
<HTML><HEAD>
<TITLE>S-3ASR</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on August&nbsp;25, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-3</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">06-1376651</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3611 Valley Centre Drive, Suite 300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA 92130 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">(858)&nbsp;558-2871</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of
Registrant&#146;s principal executive offices) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stephen R. Davis </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(858)&nbsp;558-2871</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Austin&nbsp;D. Kim</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>L.&nbsp;Kay&nbsp;Chandler, Esq.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Executive&nbsp;Vice&nbsp;President,&nbsp;General&nbsp;Counsel&nbsp;and&nbsp;Secretary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Sean M. Clayton, Esq.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>ACADIA Pharmaceuticals Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Cooley LLP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>3611 Valley Centre Drive, Suite 300</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>4401 Eastgate Mall</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>San Diego, CA 92130</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>San Diego, CA 92121-1909</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">558-2871</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">550-6000</FONT></B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">From time to time after the effective date of this Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box:&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering:&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this
Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering:&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall
become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box:&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form
is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box:&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, or a smaller reporting company. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares&nbsp;to&nbsp;be<BR>Registered&nbsp;(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed<BR>Maximum<BR>Offering&nbsp;Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per&nbsp;Share&nbsp;(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed<BR>Maximum<BR>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering&nbsp;Price&nbsp;(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration&nbsp;Fee</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, $0.0001 par value</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">1,174,208</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$38.42</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">$45,113,071.36</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">$5,855.68</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416 under the Securities Act, the shares being registered hereunder include such indeterminate
number of additional shares of common stock as may be issuable as a result of stock splits, stock dividends or similar transactions with respect to the shares being registered hereunder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under
the Securities Act, based upon the average of the high and low prices for the common stock on August&nbsp;24, 2020, as reported by the Nasdaq Global Select Market. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g18921g97y90.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the disposition from time to time of up to 1,174,208 shares of our common stock which are held by the selling stockholders
identified in this prospectus. The selling stockholders acquired these shares from us in connection with our acquisition of CerSci Therapeutics Incorporated pursuant to the terms of the Agreement and Plan of Merger, dated as of August&nbsp;24, 2020,
by and among us, Queen Merger Sub, Inc., CerSci Therapeutics Incorporated and Shareholder Representative Services LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not selling any common
stock under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may
sell the shares of common stock described in this prospectus in a number of different ways and at varying prices. We provide more information about how the selling stockholders may sell their shares of common stock in the section entitled &#147;Plan
of Distribution&#148; on page 9. The selling stockholders will bear all commissions and discounts, if any, attributable to the sale or disposition of the shares, or interests therein. We will bear all costs, expenses and fees in connection with the
registration of the shares. We will not be paying any underwriting discounts or commissions in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq
Global Select Market under the symbol &#147;ACAD&#148;. On August&nbsp;24, 2020, the last reported sale price of our common stock was $38.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>An investment in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties referred to under the heading
&#147;<A HREF="#rom18921_2">Risk Factors</A>&#148; beginning on page 5 of this prospectus and under any similar headings in any amendment or supplement to this prospectus or in any filing with the Securities and Exchange Commission that is
incorporated by reference herein. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved
of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>August&nbsp;25, 2020 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom18921_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom18921_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom18921_3">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom18921_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom18921_5">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom18921_6">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom18921_7">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom18921_8">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom18921_9">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange
Commission, or SEC, using a &#147;shelf&#148; registration process as a &#147;well-known seasoned issuer,&#148; as defined in Rule 405 under the Securities Act of 1933, as amended, or the Securities Act. Under this registration statement, the
selling stockholders may sell from time to time in one or more offerings the common stock described in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and the selling
stockholders have not, authorized anyone to provide you with information other than the information contained or incorporated by reference in this prospectus and any related prospectus supplement. No one is making offers to sell or seeking offers to
buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus and any prospectus supplement is accurate only as of the date on the front of this prospectus or
the prospectus supplement, as applicable, and that any information incorporated by reference in this prospectus or any prospectus supplement is accurate only as of the date given in the document incorporated by reference, regardless of the time of
delivery of this prospectus, any applicable prospectus supplement or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">References in this prospectus to &#147;ACADIA,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to ACADIA
Pharmaceuticals Inc., together with our wholly-owned subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;ACADIA&#148; and &#147;NUPLAZID&#148; are our registered trademarks. Our logos
and trademarks are the property of ACADIA Pharmaceuticals Inc. All other brand names or trademarks appearing in this prospectus are the property of their respective holders. Use or display by us of other parties&#146; trademarks, trade dress, or
products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom18921_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere or incorporated by reference into this prospectus. Because it is a summary, it does not contain all
of the information that you should consider before investing in our securities. You should read this entire prospectus carefully, including the section entitled &#147;Risk Factors&#148;, any prospectus supplement and the documents that we
incorporate by reference into this prospectus, before making an investment decision. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous
system disorders. We have a portfolio of product opportunities led by our novel drug, NUPLAZID (pimavanserin), which was approved by the U.S. Food and Drug Administration, or the FDA, in April 2016 for the treatment of hallucinations and delusions
associated with Parkinson&#146;s disease psychosis, or PD Psychosis. We hold worldwide commercialization rights to pimavanserin. NUPLAZID is available in 34 mg capsule and 10 mg tablet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that pimavanserin has the potential to address important unmet medical needs in neurological and psychiatric disorders in addition to PD Psychosis
and we plan to continue to study the use of pimavanserin in multiple disease states. For example, we believe dementia-related psychosis, or DRP, represents one of our most important opportunities for further exploration. In June 2020, we submitted a
supplemental New Drug Application, or sNDA, for NUPLAZID for the treatment of hallucinations and delusions associated with DRP. In July 2020 the FDA notified us of acceptance of our sNDA with a PDUFA date of April&nbsp;3, 2021. The FDA advised us
that it has not identified any potential review issues at this point in their evaluation and at this time they are not planning to hold an Advisory Committee meeting. The sNDA is supported by results from the pivotal Phase 3 HARMONY study, which met
its primary endpoint, demonstrating that pimavanserin significantly reduced the risk of relapse of psychosis by 2.8 fold compared to placebo (hazard ratio = 0.353; <FONT STYLE="white-space:nowrap">one-sided</FONT> p=0.0023). The sNDA also includes
positive efficacy results from two additional placebo-controlled studies, both of which met their respective primary endpoints: the Phase 2 <FONT STYLE="white-space:nowrap">(-019)</FONT> study in patients with Alzheimer&#146;s disease psychosis and
the Phase 3 <FONT STYLE="white-space:nowrap">(-020)</FONT> study in patients with Parkinson&#146;s disease psychosis. The sNDA includes a large safety database from completed and ongoing studies representing over 1,500 patients with
neurodegenerative disease. An estimated 8.0&nbsp;million people in the United States are living with dementia, and studies suggest that approximately 30% of dementia patients, or 2.4&nbsp;million people, have psychosis, commonly consisting of
delusions and hallucinations. Approximately 1.2&nbsp;million patients in the United States are currently treated for DRP and, of those treated, approximately <FONT STYLE="white-space:nowrap">two-thirds</FONT> are treated with <FONT
STYLE="white-space:nowrap">off-label</FONT> anti-psychotics. In the fourth quarter of 2017, the FDA granted Breakthrough Therapy Designation for pimavanserin for the treatment of DRP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2018, we announced positive <FONT STYLE="white-space:nowrap">top-line</FONT> results from CLARITY, a Phase 2 study evaluating pimavanserin for
adjunctive treatment in 207 patients with major depressive disorder, or MDD. In July 2020, we announced that our Phase 3 CLARITY study, which combined the two identical, double-blind, placebo-controlled studies
<FONT STYLE="white-space:nowrap">(CLARITY-2</FONT> and <FONT STYLE="white-space:nowrap">CLARITY-3)</FONT> in 298 patients, did not achieve statistical significance on the primary endpoint. At this time we do not plan on initiating any additional
Phase 3 studies to evaluate pimavanserin for the adjunctive MDD indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schizophrenia remains a disease with high unmet need, and we are currently
exploring the utility of pimavanserin in this area. In the fourth quarter of 2016, we initiated our ADVANCE study, a Phase 2 study that evaluated pimavanserin for the negative symptoms of schizophrenia, for which there are currently no <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> therapies. Negative symptoms of schizophrenia have been associated with poor long-term </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outcomes and disability even when the positive symptoms are well controlled, representing a high unmet need. In November 2019, we announced positive
<FONT STYLE="white-space:nowrap">top-line</FONT> results from our ADVANCE study that evaluated the efficacy of pimavaserin compared to placebo in 403 patients with predominantly negative symptoms of schizophrenia who have achieved adequate control
of positive symptoms with their existing antipsychotic treatment. Pimavanserin demonstrated a statistically significant improvement on the study&#146;s primary endpoint, the change from baseline to week 26 on the Negative Symptom <FONT
STYLE="white-space:nowrap">Assessment-16</FONT> <FONT STYLE="white-space:nowrap">(NSA-16)</FONT> total score compared to placebo (p=0.043). A greater improvement in the <FONT STYLE="white-space:nowrap">NSA-16</FONT> total score compared to placebo
was observed in patients who received the highest pimavanserin dose of 34 mg (n=107; unadjusted p=0.0065). 53.8% of patients who were randomized to receive pimavanserin completed the trial on 34 mg, 44.7% on 20 mg, and 1.5% on 10 mg. In the study,
pimavanserin did not separate from placebo on the key secondary endpoint, the Personal and Social Performance scale. In the third quarter of 2020, we initiated a second pivotal study, <FONT STYLE="white-space:nowrap">ADVANCE-2.</FONT> The Phase 3
study will evaluate the efficacy of pimavaserin 34 mg once daily compared to placebo in approximately 386 patients with predominantly negative symptoms of schizophrenia who have achieved adequate control of positive symptoms with their existing
antipsychotic treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, we acquired an exclusive North American license to develop and commercialize trofinetide for Rett syndrome and
other indications from Neuren Pharmaceuticals Limited. Rett syndrome is a debilitating neurological disorder that occurs predominantly in females following apparently normal development for the first six months of life. Typically, between six to
eighteen months of age, patients experience a period of rapid decline with loss of purposeful hand use and spoken communication and inability to independently conduct activities of daily living. Symptoms also include seizures, disorganized breathing
patterns, scoliosis and sleep disturbances. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1, designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting
synaptic function. Trofinetide has been granted FDA Fast Track Status and an Orphan Drug Designation in the U.S. and an Orphan Designation in Europe, as well as Rare Pediatric Disease designation in the U.S. Currently, there are no approved
medicines for the treatment of Rett syndrome. In October 2019, we initiated the Phase 3 LAVENDER randomized, double-blind placebo-controlled study evaluating trofinetide in girls and young women <FONT STYLE="white-space:nowrap">5-20</FONT> years of
age with Rett syndrome. We expect results from our LAVENDER study in the second half of 2021, but we are unable to predict with certainty how the pandemic might affect the timing for completion of the study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2020, we acquired an exclusive worldwide license to develop and commercialize novel drug candidates targeting positive allosteric modulators, or
PAMs, of the muscarinic M1 receptor with the potential to treat a range of central nervous system, or CNS, disorders, from Vanderbilt University. Under the agreement, we obtained exclusive worldwide rights to certain highly selective M1 PAMs, which
represent a promising approach for improving cognitive function and other neuropsychiatric symptoms in patients suffering from CNS disorders. The agreement includes a portfolio of candidates, with molecules at various stages of testing, including a
lead compound in early Phase 1 testing, several additional compounds in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development as well as any additional compounds generated in an ongoing discovery program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in January 1997. Our principal executive offices are located at 3611 Valley Centre Drive, Suite 300, San Diego, California
92130, and our telephone number at that address is (858) <FONT STYLE="white-space:nowrap">558-2871.</FONT> Our website address is www.acadia-pharm.com. The information contained in, or that can be accessed through, our website is not part of this
prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Acquisition of CerSci Therapeutics Incorporated </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;24, 2020, we entered into an Agreement and Plan of Merger, or the &#147;Merger Agreement&#148;, by and among us, Queen Merger Sub, Inc., or
&#147;Merger Sub&#148;, CerSci Therapeutics Incorporated, or &#147;CerSci&#148;, and Shareholder Representative Services LLC, and on the same day, the transactions contemplated by the Merger </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement closed and Merger Sub merged with and into CerSci, with CerSci as the surviving corporation and our wholly-owned subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CerSci is a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including <FONT
STYLE="white-space:nowrap">non-opioid</FONT> therapies for acute and chronic pain. CerSci&#146;s lead development program is a unique Reactive Species Decomposition Accelerant, a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> mechanism focused on interrupting pathways that sensitize neurons to pain. The portfolio contains additional preclinical stage molecules, including brain
penetrant molecules, with potential for symptomatic and disease modifying treatment utility in neurodegenerative diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the
Merger Agreement, in connection with the closing of the transactions contemplated by the Merger Agreement, the former holders of CerSci&#146;s capital stock, warrants or options, or collectively, the &#147;CerSci Equityholders&#148;, were entitled
to $52.5&nbsp;million as upfront consideration, subject to certain adjustments, $47.2 million of which was paid through the issuance of 1,174,208 shares of our common stock at closing. In addition, CerSci Equityholders may be eligible to receive up
to $887.0&nbsp;million in development, commercialization and sales milestones, and tiered royalties in the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits based on annual net sales, which milestones and royalties would be payable in cash.
Under the terms of the Merger Agreement, we agreed to file with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> to register for resale of the shares of our common stock that we issued as part of the
consideration for the merger at closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stockholders are not considered third-party beneficiaries under the Merger Agreement and should not rely on
the representations, warranties, covenants or any descriptions thereof as characterization of the actual state of facts of condition of us, CerSci or any of our respective subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Throughout this prospectus, when we refer to the shares of our common stock, the offer and sale of which are being registered on behalf of the selling
stockholders on the registration statement of which this prospectus is a part, we are referring to the shares of common stock held by former holders of the capital stock of CerSci, that we agreed to register pursuant to the Merger Agreement. When we
refer to the &#147;selling stockholders&#148; in this prospectus, we are referring to former holders of the capital stock, warrants and options of CerSci. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock to be Offered by the Selling Stockholders </P></TD>
<TD>1,174,208 shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market Symbol </P></TD>
<TD>ACAD </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders named in this prospectus may offer and sell up to 1,174,208 shares of our common stock issued by us
pursuant to the Merger Agreement. We agreed to file the registration statement to which this prospectus forms a part to register these shares pursuant to the Merger Agreement. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom18921_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An investment in our common stock involves a high degree of risk. Prior to making a decision about investing in our common stock, you should consider
carefully the specific risk factors discussed in the sections entitled &#147;Risk Factors&#148; contained in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2020, as filed with the SEC
which is incorporated in this prospectus by reference in its entirety, as well as any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including any prospectus supplement hereto. These risks and uncertainties
are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings
or any additional risks and uncertainties actually occur, our business, financial condition, results of operations and cash flow could be materially and adversely affected. In that case, the trading price of our common stock could decline and you
might lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom18921_3"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains, and the documents incorporated by reference herein and any applicable prospectus supplement may contain, forward-looking statements
within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to future events or to our future financial performance and involve
known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking
statements. Forward-looking statements may include, but are not limited to statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits to be derived from NUPLAZID<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pimavanserin)
and other drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential market opportunities for pimavanserin and other drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategy for the commercialization of NUPLAZID; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans for exploring and developing pimavanserin for indications other than in Parkinson&#146;s disease
psychosis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans and timing with respect to seeking regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential commercialization of any of our drug candidates that receive regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, timing, results or implications of clinical trials and other development activities involving
NUPLAZID and other drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategy for discovering, developing and, if approved, commercializing drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our existing and potential future collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of future payments, revenues and profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding our capital requirements, future expenses and need for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential or expected impact of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our
business; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">possible changes in legislation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;could&#148;,
&#147;would&#148;, &#147;expects&#148;, &#147;plans&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;estimates&#148;, &#147;projects&#148;, &#147;predicts&#148;, &#147;potential&#148; and similar expressions (including their use in the
negative) intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place
undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the heading &#147;Risk Factors&#148; in our SEC filings, and may provide additional information in any applicable prospectus supplement. Also,
these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You
should read this prospectus, the registration statement of which this prospectus is a part, the documents incorporated by reference herein, and any applicable prospectus supplement completely and with the understanding that our actual future results
may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. Unless required by law, we undertake no obligation to update or revise any forward-looking
statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom18921_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale of shares of our common stock by the selling stockholders pursuant to this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each selling stockholder will pay any underwriting discounts and commissions and any expenses incurred by the selling stockholder for brokerage, accounting,
tax or legal services or any other expenses incurred by such selling stockholder in disposing of shares covered by this prospectus. We will bear all other costs, fees and expenses incurred in effecting the registration statement of which this
prospectus forms&nbsp;a part, including, without limitation, all registration fees, any applicable listing fees of the Nasdaq Global Select Market and fees and expenses of our counsel and our accountants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom18921_5"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering for resale an aggregate of 1,174,208 shares of our common stock that may be sold by the selling stockholders set forth herein. The shares
registered hereby were issued to the former holders of the capital stock, warrants and options of CerSci in connection with the closing of the merger pursuant to the Merger Agreement and were issued pursuant to the exemption from the registration
requirements provided in Section&nbsp;4(a)(2) of the Securities Act for transactions by an issuer not involving any public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
Merger Agreement, we agreed to file with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> to register for resale the shares of our common stock that we issued as part of the consideration for the merger at
closing. We agreed to promptly file any documents with the SEC as may be necessary to keep such registration statement effective for a period of six months, or if earlier, the date on which all such shares of common stock have been sold pursuant to
an effective registration statement, or prospectus supplement. We also agreed to use reasonable best efforts to make available to the selling stockholders the benefits of Rule 144 of the Securities Act and any other rule or regulation of the SEC
that may at any time permit a holder to sell shares of our common stock to the public without registration until the date on which all such shares of common stock have been sold pursuant to an effective registration statement, or prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC, and includes voting or investment power with respect to our
common stock. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all shares of common stock that they
beneficially own, subject to applicable community property laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell some, all or none of their respective shares of common
stock offered by this prospectus from time to time. We do not know how long the selling stockholders will hold their respective shares of common stock covered hereby before selling them. Other than the Merger Agreement and the agreements
contemplated thereby, we currently have no agreements, arrangements or understandings with the selling stockholders regarding the sale of any of the shares of common stock being offered hereunder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;Shares&nbsp;Beneficially&nbsp;Owned&nbsp;&nbsp;<BR>Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Number of<BR>Shares to be<BR>Sold&nbsp;Pursuant<BR>to this<BR>Prospectus</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>&nbsp;&nbsp;&nbsp;After Offering (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Number&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Selling Stockholders (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,174,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,174,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent of the outstanding shares of our common stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The selling stockholders collectively beneficially own less than one percent of the outstanding shares of our
common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The selling stockholders may offer and sell all or part of the common stock covered by this prospectus, but no
estimates can be made as to the amount of shares of common stock that will be held by the selling stockholders after the completion of this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom18921_6"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders and any of their pledgees, assignees and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may, from time to time in one or more transactions on Nasdaq or any other organized market where our shares of common stock may be traded, sell
any or all of their shares of our common stock offered hereby through underwriters, dealers or agents, directly to one or more purchasers or through a combination of any such methods of sale. The selling stockholders may distribute the shares of our
common stock offered hereby from time to time in one or more transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may use any one or more of the following methods when selling the shares offered hereby: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on any national securities exchange or quotation service on which the securities may be listed or quoted at the
time of sale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions otherwise than on these exchanges or systems or in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options, whether such options are listed on an options exchange or
otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">one or more block trades in which the broker-dealer will attempt to sell the shares as agent or principal of all
such shares held by the selling stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agreements between broker-dealers and the selling stockholder to sell a specified number of such shares at a
stipulated price per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method or combination of methods of sale permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may also sell shares pursuant to Rule&nbsp;144 under the Securities Act, if available, rather than under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the selling stockholders effect such transactions by selling shares of common stock offered hereby to or through underwriters, broker-dealers or agents,
such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions from purchasers of the shares of common stock offered hereby for whom they may act
as agent or to whom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions involved). In connection with sales
of the shares of common stock offered hereby or otherwise, the selling stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the shares of common stock offered hereby in the course of
hedging in positions they assume. The selling stockholders may also sell shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock offered hereby short and deliver shares of common stock covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The
selling stockholders may also loan or pledge shares of common stock offered hereby to broker-dealers that in turn may sell such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling
stockholders may from time to time pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and
sell the shares of common stock from time to time under this prospectus or any amendment to this prospectus under Rule&nbsp;424(b)(3), or other applicable provision of the Securities Act, supplementing or amending, if necessary, the list of selling
stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the
transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders and
any broker-dealer participating in the distribution of the shares of common stock offered hereby may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. In such event, any commissions
received by such broker-dealers or agents and any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Any such discounts, concessions, commissions
and similar selling expenses, if any, attributable to the sale of shares will be borne by a selling stockholder. The selling stockholders may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of
the shares if liabilities are imposed on that person under the Securities Act. At the time a particular offering of the shares of common stock offered hereby is made, a prospectus supplement, if required, will be distributed which will set forth the
aggregate amount of shares of common stock being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling stockholders
and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the securities laws of some states, the shares of
common stock offered hereby may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares of common stock offered hereby may not be sold unless such shares have been registered or qualified
for sale in such state or an exemption from registration or qualification is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that any selling
stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement, of which this prospectus forms&nbsp;a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders and any other person participating in such distribution will be subject to the applicable provisions of the Exchange Act, and the
rules and regulations promulgated thereunder, including, without limitation, Regulation&nbsp;M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of common stock offered hereby by the selling stockholders and
any other participating person. Regulation&nbsp;M may also restrict the ability of any person engaged in the distribution of the shares of common stock offered hereby to engage in market-making activities with respect to the shares of common stock
offered hereby. All of the foregoing may affect the marketability of the shares of common stock offered hereby and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock offered hereby.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once sold under the shelf registration statement, of which this prospectus forms&nbsp;a part, the shares of common stock will be freely tradable in the
hands of persons other than our affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom18921_7"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the common stock being offered by this prospectus will be passed upon for us by Cooley LLP, San Diego, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom18921_8"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements (and schedule) included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2019, as set forth in their reports, which
are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements (and schedule) are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports, given on their authority as
experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom18921_9"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a reporting company and we file annual, quarterly and current reports, proxy statements and other information with the SEC. We have filed with the SEC
a registration statement under the Securities Act with respect to the common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration
statement or the exhibits which are part of the registration statement. For further information with respect to us and the common stock offered by this prospectus, we refer you to the registration statement and the exhibits filed as part of the
registration statement. Our SEC filings are available to the public from the SEC&#146;s website at www.sec.gov. We maintain a website at www.acadia-pharm.com. The information contained in, or that can be accessed through, our website is not part of
this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with it, which means that we can disclose important information to you by
referring to those documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference the following documents we filed with the SEC pursuant to Section&nbsp;13 of the Exchange Act and any future filings we will make
with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act after the date of this prospectus until the termination of the offering of the shares covered by this prospectus (other than information furnished under Item 2.02 or Item
7.01 of Form <FONT STYLE="white-space:nowrap">8-K):</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1070494/000156459020006889/acad-10k_20191231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The information specifically incorporated by reference into our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1070494/000156459020006889/acad-10k_20191231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;
31, 2019 from our definitive proxy statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000156459020019815/acad-def14a_20200623.htm">Schedule 14A</A> (other than information furnished rather than filed) filed with the SEC on
April&nbsp;29, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1070494/000156459020023050/acad-10q_20200331.htm">March
<U></U>&nbsp;31, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1070494/000156459020036993/acad-10q_20200630.htm">June<U></U>&nbsp;30, 2020</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1070494/000119312520182326/d23206d8k.htm">June
<U></U>&nbsp;29, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1070494/000119312520195481/d120197d8k.htm">July<U></U>&nbsp;
20, 2020</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1070494/000119312520212084/d18126d8k.htm">August<U></U>&nbsp;
6, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1070494/000119312520229278/d89886d8k.htm">August&nbsp;25, 2020</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000119312504091609/d8a12g.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> dated May&nbsp;19, 2004. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may access our annual report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> Proxy Statement, and amendments, if any, to those documents filed or
furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at the SEC&#146;s website or our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC.
The reference to our website does not constitute incorporation by reference of the information contained in our website. We do not consider information contained on, or that can be accessed through, our website to be part of this prospectus or the
related registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of our SEC filings at no cost, by telephoning or writing us at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ACADIA
Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3611 Valley Centre Drive, Suite 300 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">San Diego, CA 92130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(858) <FONT
STYLE="white-space:nowrap">558-2871</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Other Expenses of Issuance and Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the costs and expenses, payable by us in connection with the offering of common stock being registered. All amounts are
estimates except the registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount<BR>to<BR>Be Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the Delaware General Corporation Law allows a corporation to eliminate the personal liability of directors of a corporation to the
corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law,
authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the
corporation and certain other persons serving at the request of the corporation in related capacities against amounts paid and expenses incurred in connection with an action or proceeding to which he is or is threatened to be made a party by reason
of such position, if such person shall have acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interest of the corporation, and, in any criminal proceeding, if such person had no reasonable cause to
believe his conduct was unlawful; provided that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any matter as to which such person shall have been adjudged to be liable to the
corporation unless and only to the extent that the adjudicating court determines that such indemnification is proper under the circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended
and restated certificate of incorporation and bylaws include provisions that indemnify our directors and officers for actions taken in such capacity, if the actions were taken in good faith and in a manner reasonably believed to be in our best
interests and, in a criminal proceeding, the director or officer had no reasonable cause to believe that his or her conduct was unlawful. A director or officer who is successful in defending a claim will be indemnified for all expenses incurred in
connection with his or her defense. We have entered into indemnification agreements with our officers and directors that require us to indemnify such persons against any and all expenses (including attorneys&#146; fees), witness fees, damages,
judgments, fines, settlements and other amounts incurred in connection with any action, suit or proceeding, whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is or was or at any time
becomes a director, an officer or an employee of ACADIA or any of our affiliated enterprises, provided that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interest and, with
respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain directors and officers insurance
providing indemnification for certain of our directors, officers, affiliates, partners and employees for certain liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000119312515281018/d937801dex31.htm">Amended and Restated Certificate of Incorporation, as Amended (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Quarterly Report
 on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> filed August<U></U>&nbsp;6, 2015).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000141588913001809/acadiaexhibit.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> filed September<U></U>&nbsp;12, 2013).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Reference is made to Exhibits <A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000119312515281018/d937801dex31.htm">3.1</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000141588913001809/acadiaexhibit.htm">3.2</A> above.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000091205700054458/a2033472zex-4_1.txt">Form of common stock certificate of the Registrant (incorporated by reference to Exhibit 4.1 to Registration Statement No.<U></U><FONT
STYLE="white-space:nowrap">&nbsp;333-52492).</FONT></A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000156459019004596/acad-ex42_574.htm">Form of Amended and Restated Warrant to Purchase Common Stock (superseding the form of warrant issued to certain purchasers in a private placement
 on December<U></U>&nbsp;17, 2012) (incorporated by reference to Exhibit 4.2 to the Registrant&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> filed February<U></U>&nbsp;27, 2019).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d18921dex51.htm">Opinion of Counsel. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d18921dex231.htm">Consent of Independent Registered Public Accounting Firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d18921dex51.htm">Consent of Counsel (included in Exhibit 5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included on signature page) </A></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the
effective registration statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided, however,</I> that
subparagraphs (i), (ii) and (iii)&nbsp;above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to
Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability under the Securities Act to any purchaser:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule
430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective
date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#146;s
annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the provisions of Item 15 above, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on
August&nbsp;25, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ACADIA PHARMACEUTICALS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;/s/ Stephen R. Davis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Stephen R. Davis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Stephen R.
Davis and Austin D. Kim, and each of them, as his or her true and lawful attorneys in fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign
any and all amendments to this registration statement and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys in fact and agents full
power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that
said attorneys in fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates
indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Stephen R. Davis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stephen R. Davis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Executive Officer, Director<BR><I>(Principal Executive Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">August&nbsp;25, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Elena H. Ridloff</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Elena H. Ridloff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Executive Vice President and Chief Financial Officer<BR><I>(Principal Financial Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">August&nbsp;25, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ James K. Kihara</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James K. Kihara</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Vice President and Corporate Controller<BR><I>(Principal Accounting Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">August&nbsp;25, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Stephen R. Biggar</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stephen R. Biggar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">August&nbsp;25, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Julian C. Baker</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Julian C. Baker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">August&nbsp;25, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Laura A. Brege</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Laura A. Brege</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">August&nbsp;25, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ James M. Daly</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James M. Daly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">August&nbsp;25, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Edmund P. Harrigan</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Edmund Harrigan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">August&nbsp;25, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Daniel B. Soland</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Daniel B. Soland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">August&nbsp;25, 2020</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d18921dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g18921g0824224947796.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sean M. Clayton </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">T: +1 858 550
6034 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">sclayton@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 25, 2020 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3611 Valley Centre Drive, Suite 300
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92130 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You have requested our opinion, as counsel to ACADIA Pharmaceuticals Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), with
respect to certain matters in connection with the filing by the Company of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;) with the Securities and Exchange
Commission, including a related prospectus filed with the Registration Statement (the &#147;<B><I>Prospectus</I></B>&#148;), covering the registration for resale of up to 1,174,208 shares of the Common Stock, $0.0001 par value, of the Company on
behalf of certain selling stockholders (the &#147;<B><I>Shares</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this opinion, we have examined and
relied upon the Registration Statement, the Prospectus, the Company&#146;s Certificate of Incorporation and Bylaws, each as currently in effect, and originals or copies certified to our satisfaction of such records, documents, certificates,
memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals,
the conformity to originals of all documents submitted to us as copies and the due authorization, execution and delivery by all persons other than the Company of all documents where authorization, execution and delivery are prerequisites to the
effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that
any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares have been validly issued and are fully paid and
nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We consent to the reference to our firm under the caption &#147;Legal Matters&#148; in the Prospectus and to the filing of
this opinion as an exhibit to the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;/s/ Sean M. Clayton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;Sean M. Clayton</TD></TR>
</TABLE> <P STYLE="margin-top:160pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">4401 EASTGATE MALL, SAN DIEGO, CA 92121 T: (858) <FONT STYLE="white-space:nowrap">550-6000</FONT> F: (858) <FONT
STYLE="white-space:nowrap">550-6420</FONT> WWW.COOLEY.COM </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d18921dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; in this Registration Statement (Form S-3) and related Prospectus of ACADIA
Pharmaceuticals Inc. for the registration of shares of its common stock and to the incorporation by reference therein of our reports dated&nbsp;February 26, 2020, with respect to the consolidated financial statements and schedule of ACADIA
Pharmaceuticals Inc., and the effectiveness of internal control over financial reporting of ACADIA Pharmaceuticals Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2019, filed with the Securities and Exchange
Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Ernst &amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 25, 2020 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g18921g0824224947796.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g18921g0824224947796.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L (@# 2(  A$! Q$!_\0
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:SY6Y\S.]XJ$<&J%-.[=Y/\D+1116AYY__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g18921g97y90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g18921g97y90.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( +0
M? ,!$0 "$0$#$0'_Q  =  $  @(# 0$             " D'"@4&"P0#_\0
M21    8" 0$$ PL'" L      @,$!08' 0@ "0H1$A,4%1<6(38Y56%U>)6T
MU"(Q,E&!MK<C)"DS04)Q=Q@9)B<W4W."H:+!_\0 '@$!  $$ P$!
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M7+3A$X1.$5HG2HZ=<JZ@.P;:S.*%R;J#KM8VO]VS(D)J<O#1@[)R*!LB_&,
M]UDVRG.0I<E#R8S,X'61C =EM3HEWQ3TX^EM8^BKLHK+A25-'5[4M6T]9:MF
M^GI#',_]O[6(ZG5%RI22?["TV)HZJ</;N7&X.H;0UT8K)JFE[5I/3<VH;BUC
MFN;;Z9S9*Z89 W,Y%/&[_?3X+1CC&S?E(.Z&N]'2/1]DB;"R1:,M2!BCD;:&
MU@8&1K3%(VQG96=&2WM;6W)"0@)2H6]"G(2)$Y00EDD%%E@#@(<8YY#;K=;E
M?;I<KW>:ZJN=WO%?672ZW*MF?45MPN-PJ)*NMK:NHD+I)ZFJJ999YYGN+Y)9
M'/<222OI....&-D43&QQ1,;''&P!K6,8 UK6@< UK0  .0"YCGYZK3A$X1.$
M3A$X1.$3A%(>I?@XM^FU/W!MYO"[&E[1.K/C:OOX.T&L0;0/9FF^#(?O5:J.
M>U@?%?1WZU-4?N;:O/0J>8\OH*PG#W_F*\V[DKEIPB<(K3NG3TG]A-_I.@=V
MYN6UMK\@<<%2VZY V'8;3RDQV +F2O6\_*<4UE'<$PD8$9H&)C,QXY [(CAH
MD+A\1=+CIT[*.BO9:J@JZNFUAM5JJ0OL.SBU5D9K(GS1EU-<M65<0F&G++DL
MD#JACKG<F'=M5#4QMJ:FD[7IO2-QU#*U[6NI;<UV)JZ1AW2 >Z93-..WR\P<
M$1QG_$>T[K7>@)K+K+3VHM/QJDJ0C!4;AL=+$:<<:("E]D[ZI+*"ZRR6.V"B
M37J2/)A)8UJXPLHDD@I*V-B5O9F]N;DGE8VS;9MH&WO7]YVD[2;R^\:AN[Q'
M'&P.AMEEMD+I#0V*Q4)?(RW6>W-D>VFIF.?))))/6UL]7<*NLJZCZ%M=KHK/
M1Q4-#%VJ"+B2>,DLAQOS3/P"^5Y'=.P   QC6L:UK<_<Q6OT$X1.$3A$X1.$
M3A$X1.$4C*A^#2[Z<4_<&SF\SL9?M#ZM^-R_?@W02PWM#]FJ7X+@^]UJK:[0
M%I[<6[VBK/35'E1DZ9I+[K^;&@E;Y[GVSU(QQJ?-Z[(5_H:WO5^D/:'R4^2<
M8,!DT7F!\ON%N=V_=(#9]T;-#4^T/:5)>8].SW^WZ<8ZQVS^U:W^TKE2W"JI
M@ZE_:*;$':K;4]LE[8=QP8W=._PQ=8+-6WVN-%0"(SM@DG/;I.UM[6QS&N[K
M#N.9&X&./'P+2>-[.KU(B_T&"G3_ /I6JAQ^K_G-1/Z__&?F[_C=G9;NA^_O
MKIM!C_SZ'J3_ /772+N1V;ZE_P!W1'R5;?2P+(M?]FJWMDJ\@,XF=!ULT>,/
MIBE5+I)*G@!6<XP(2!ICT1-;E9H<=^?*5R%L+%W=V#^_G4M5=F+Z,5GI9#IK
M3NU+6%?NG]GAAL%GL=O<\#(%577:_P =73QD\-^GM-:X?[K"Y-/LRO\ *X=O
MGM],SK)FEE?C^5D<):3XC(WRJZS4SL[&H-&+FR5WD\ONT,R;QDJ2FV3-Y,1J
ME.K*S@P!F8"VKW-<_>6/Q%FII7*GMB7DX#Z1'@YR(/-<FW;LMNWW:935ECV9
MVZV;%=/539(7UEFJI+]KF:!X+',&J:REHJ6U[S,.9-8[';KG32$]INSL-*[O
M:-G%FH'-EKWR769N"&RM[32 CC_V=KG.DX\Q-*^-PYQJ_=G9FB/-3<Q,#4VL
M;&SHT[<TLS.A2MC4UMZ0H)"1 W-R(HA(B1I20 )3I4Q)1!)00EE@" .,8U97
M"X5]VKJNYW6NK+G<KA42U=?<+A4S5M=6U=0\R3U575U+Y*BIJ)I'.DEFFD?)
M(]Q<]Q<25D%C&1L;'&QL<;&AK&,:&,8T# :UK0&M:!P    Y+DN<-5)PB<(G
M")PB<(G")PB<(G"*1E0_!I=].*?N#9S>9V,OVA]6_&Y?OP;H)8;VA^S5+\%P
M?>ZU=UO;X%$?.^H?NJ_/_P Y]:=F(..BC9A_%MBT@!_Z=UH[CYFKKFRS_O+-
MXK55?>*,>E0^YY?U]#IPB<(G")PB<(G")PB<(G")PB<(G")PBD94/P:7?3BG
M[@V<WF=C+]H?5OQN7[\&Z"6&]H?LU2_!<'WNM64+7CCO*(R0W,J8*I6!V2JA
M%#/(3X\@I.L+&+S%!A1><X&<7CPX%XL]_?C&<8SS8=V2#85M-Z0NP*TZ%V46
M*GU#J6FVE:>U%44-1>+/9(V6BWV/55'55 K+W74%&YT=5<J%@@;.9WB4O9&Y
MD<CF])T%>;?8[U+67*9T%.ZWSP->V*68]M?-3/:W<A8]_%L;SO;N!C!/$*.?
ML;L'Y&)^U6O\9S1AZUGTV/>MM7TB;//U,LQ>J-I'W2D^85_Y9/8W8/R,3]JM
M?XSCUK/IL>];:OI$V>?J9/5&TC[I2?,*_P#+)[&[!^1B?M5K_&<>M9]-CWK;
M5](FSS]3)ZHVD?=*3YA7_ED]C=@_(Q/VJU_C./6L^FQ[UMJ^D39Y^ID]4;2/
MNE)\PK_RR>QNP?D8G[5:_P 9QZUGTV/>MM7TB;//U,GJC:1]TI/F%?\ ED]C
M=@_(Q/VJU_C./6L^FQ[UMJ^D39Y^ID]4;2/NE)\PK_RR>QNP?D8G[5:_QG'K
M6?38]ZVU?2)L\_4R>J-I'W2D^85_Y9/8W8/R,3]JM?XSCUK/IL>];:OI$V>?
MJ9/5&TC[I2?,*_\ +)[&[!^1B?M5K_&<>M9]-CWK;5](FSS]3)ZHVD?=*3YA
M7_ED]C=@_(Q/VJU_C./6L^FQ[UMJ^D39Y^ID]4;2/NE)\PK_ ,LGL;L'Y&)^
MU6O\9QZUGTV/>MM7TB;//U,GJC:1]TI/F%?^63V-V#\C$_:K7^,X]:SZ;'O6
MVKZ1-GGZF3U1M(^Z4GS"O_+)[&[!^1B?M5K_ !G'K6?38]ZVU?2)L\_4R>J-
MI'W2D^85_P"63V-V#\C$_:K7^,X]:SZ;'O6VKZ1-GGZF3U1M(^Z4GS"O_++,
MU=PN11]D5(W5"!.H-=#U( !5I#L9)&D0E!%XR3S XSD9)F/#G.!8\/?G'=G&
M<[3^@_T3MN>Q?9/J'2VT32=)9KU7[0[M?Z6E@U)INZLDM=5IO25N@J#46JZ5
ME.QSJNU5L9A?*V9HB#W1ADD;G8WUCJ2SW>YP5-!5.EA90Q0.<ZGJ(B)&U%5(
M6[LD37'#96'(&..,Y!6<N;?EB]<'B3QH4E,A@9 R9F!3&3)S8KAU0YD9<:4+
MSVHB0#9,'^L@,ASHF4-I3J)-A"8O(.2!/RH+&7@BYSA%\JY<A:T2MR<UB5N;
MD"8Y8N7KE!*1$B2)BQ'*%2M4H&60F3$% &:<><8 HHL(AC$$(<YP11!_UBO3
M]Q(A1'.\FH.)0 _*03!G9*G,.P5>!>#*/*',R\_"S _R,I/!Z1@7Y.2N_P![
MA5;KOX7?(5+=H>&B0-B)Z871N>V9R3@5MSLT+DSDV."4W'>6I1+T9IR54G,Q
M[X#B#3"QX]\(L\*E?+)9+'(9'GR72]_9HK%(PTN#]))-(W-$R,$?8VE*:N='
MEZ>'(],WM;6VHB#E:]P7*"$J1,48>>:64 0L$7,A$$80C ((P##@0!AS@01!
M%CO"((L=^!!%C.,XSC.<9QGOQ[W"+JLFGT%A>"\S&:1.)X-+\XK,FD;.PX,)
M\0@>:7ET6)?&7XP"!XP]X?$$0>_OQG&"+HJ/8[7EP6%MZ"^*97.!P\%$H4=H
M0A2L-,SG&,%EIB7P9PQYSG&, "#(LYSC&,<*<'P'Y%F0 P&@ :4,)A9@0C+,
M + P# /&! & 8<Y"((@YP((@YS@6,XSC.<9X4+JTKG<'@B=$KG$RBD-2N2D2
M)N4RN0M$>3KU@2A'B2(CG=8C+5*0D &<(@@1AN"@",R#P!SG!,9Y+BH[;-62
M]V]01*RZ_E#[E(<OPRQV91Q[=O04XRBU"WU<VN2E9Z(0,\@!RGR?)*&<4$8P
MY,!C),=?4L@<(N"C\HC4L2*W"+2%DDB!O>GZ-KUK"ZH7=(BD46=UD?DS"K4-
MYZ@I,\QY^;G!E>VPX8%K4ZH5;>N)(5ISB@$7.\(G"+3AUSV#L*/]HG3W]+5N
M"Z'ZD,2V"H"DUPE!_JLYBU8ER^L8RM*(/SX"393*M>"'YB,3X\*M)<"=5@!>
M7508(KQ ,6!S9@G_ ,0S]6>OP+<:..)3DFJ%!I9!!!8SCSSAA*)))*#D9AII
M@\A 666 (AC&,6 @#C(A9QC&<\*RM976=U5]>/9"\KGMM<[+^EYK!9AE4:_Z
M]I%Z]KA>S=I1XE([O-NW@G1')#9Q&V=O6Q][B\$=?,CA)4F96]:B$>TS4N8%
M=/\ =@ =^>)/\(Z@/'X3S\Q5\$GT\U/F=>J:FDVM5$NU:*FT;1F$'55"2HXF
M0")\D!;:VI64@AI-3 \(D*MK"C6-YQ92E">G4$E&@*WO$'.3GPYXJ%_2?TR/
MT$BVW^MK.VR!/439N/*["U_='P2I0!QJ*R*9I!\0-*%S5Y$<[^X:7%R^!N#F
M:(1ZYQCBA8I$)2I-&(JGNWL'KW<'R@GT841NT=>T.S=,DFJM1=QTUMDFTKJE
MB;)AX19H[3^M'FZK!\DI)XE"E<[S(BJ8:TI?+$G5.LL1IU&0@,]\ICP' GD,
M#SG@/2?,58?TH]A,;2=.?4"Z#EN'%Z?*8C,;EZS)GF&*9W6P3ZUG:DWOSD98
MU<NB3PLP69G(PEJ"_P H8<A,$5+QNN</']1XCZE4)VJFA*?D?3\,V!=*\BAU
MV5[9M51:-6D!D0%3I)#7EYD*9?"C9,42!V5Q Q2_N#N5'%:HYH3/9HG9,D)7
MF&J!E<A)WL9.,$XZOD5J]6=,3IU.%!UM%G/1S5)R;U5;0\"Y6MH6LSI N4J(
MTW95.RN4"C?NE.?59PS%*E^$[9>#51@U(UV3Q9,X5LN=D]T[@3UGZN/!4F[B
M1ZU.SU6S4NS^J\EL&7=,^T+!05YL#J#*I0]3=@IQY>BU2]))J6629>X.<5+=
MVIO>%#3@QP*(+E#*CC4F='ADD[ BC97&XE!:0 X#(=RSY?#X_L6P5M=7]![;
M:86,OED1@5PUS+Z#F,Z@#M(8ZTR-*0ED=:.3K&9O$%+LB/4,;OZO6HW1E?VH
M2%V0F93J4BD@\L @E;&0X=1R/M5._9;Z2J9@Z;,.NAMKN&$6W.;)N)-(K+Q&
MV@4\7M+7*PQY P#EHT@GX$?2H6%$,EB+7@:@*\J%H4F%:I2<:5<Q._CJP%=E
MO%=:O7?4386X6@@:R4Q*L9$7 6PON\U[L^2D!B56Q\GQ9Q_+2&Q7V,,A/=WB
M\U>#P &+N (K;1D@>$\?)U_4J->S3O,WJ&&;V]/2VW,MRM#33:M]PK584*32
M7./6(6M;,.;*);X%:QE=)774GEB9::7A0,B9(CEF"S%9(1%<EP=UPY.;]G]!
M;.G"M*'^_P#L+_HJ:6;+7\G5)T;W7M3R93"S%:A.D3&V._)PQ6LT2A4J&6G3
MDN-@OL:0&'G#P64!3DP7?X>[)5-&7 >$_5U_4M7GJ\+M=]8]->D]9^OM\TG9
MEK]-.Z*20@:H%:\&D\GD\?Q'F9?8CSAO9GY:YN7NGGM8QA:_^-,(@\I^=%:W
M("<G!&5UF7.>"" \'JY>#R8S]BV0.HU;.6CIA[AW!7+IE2%=I[;,EA3^WC%C
M.$\IK%U]0R)"8'.!!$F3NR9X2F?W<E%BSC.,9QPK31W31_,!]:@OV9Y@:F?H
M^Z\N+<64!9*YA?+^_"+P' SG5-=DYBQ)A^<>^(W#'&F8K&1?E>042']' >%5
M+_B.\WV!7W<*VG"*E]->6N4PZG>VJ^Z[BIN',.N&N59ZDQB-6+8\,C)CT^7@
M8?>FP*Y*@D;TW*#D*F/%4'$5IZ,HTD2U@>&X\\"E&H3A*O!W6XSQ)/#Q<!R\
M_H4'^S*6&UQFN=Z-&TLO:IH1J%MO,R83(F=Y0/;0^UC.7!Y8V1SCSFVGJ&]W
M9E\DK252,MR;CCDIV)2G,\> J",C*J7FUW\31_7UK+G:C/BFIW_G-2O[RG<)
M#W_F*OAJ+_A/6'^7D*_=MMX5L\SY3]JJWZ_D19ICTB-S4;R228%EAD.ES8<8
M$.3$CS$[2@SZW')C,X\11QQJ+* 8@9"(U,L4)A9R4>8$151]^WR^A=(Z6$I>
M9AT&:,=GXTXY<DU'M*+$#/$(0\,T'%8L*CA0<B[\^21'H^UDIP_HA3EE!#W!
MQC'"EW^(?\RQQV8GXHRGO\R[Q_B2\\*9N_\ ,%*'J36C7 +CZ>^N-D6!":^B
M-C;)CV!L1UGDJ8HM'U-?Z?, K49F5:I?US>WJ!OM\K:/(3(SS\X5IT;GD"92
M%,?Y)4-'!Q'@Q\O#[,_],JJZO+DJ6GNTU.Y]4VC7<^KGJ(:I(B'E57LUC<LC
MK5;T!:#AH2'-1&W)>E02%4V44I&G(4C 8M/L81@ &JE_B"5S!,7$<6N^H_\
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M;5:'9M?FIL?&9:G<FAY;T3LU.*4>#4J]M<4Q:Q"M3&8]XQ.J2G%'DCQ[PRS
MBQ^?A653G#-'M_$W4%:=\;(V<U?ERH%0)=<E=3M&O-G,L:BE+K;#CU@2PRN'
M55?3HYM]G/:YD-SF72CW2-@\K,H%$>$SI6U"WE7O-W=W=(XYSO9XX(Y8'#BK
M6[42VDN@$B24J\5^P6<>0C!%G>THU(9A D)V7)%ER,D,:BLIA+^[$C9<.12(
MAOE+0(#F8B/4'FI"E"4\J/+R^3T'[%2MTHNEEMOTQ'&7PU%M52]JZ\6?/E5C
M3>M3J*F$7?HW)5+)EI4.%5R-+;BYL8<NA2",H'E')(_)D9[3'&\MO+;5H3U:
MDKCWA^.YP1PSG.?+PX_*%G;<CI2LEWW[&-VM7;E?].=Y8<C*;<7+$H\WRR'6
MDP)DA:$N*W;6J]4VM\V;S6U.G8\.GIZ9:%G*1I7=+(T[#&DC.4-?@%I&\T]7
M+!\(/'"YD]NZVRZ,G13,@Z9S"_'I!-WMD;$NRKLO1^,'D9D"*FG1K)8_790,
MY6)T*^T%S$%>$&%"-4@\:(1.X_F\G#[?_P \7C45W'I'[9,&F]U:IUSNW#5L
MJW"E%D3S<S96T*2D+_:UD22R4,<C[RT5^WLELM,;@L.40QA%#U+4YIY28F:7
M!P]SHH\)66!&4[XW@[=[W&Z <  >'N3GCU\%;IJ96EL4U0E>5-<$EK"6/]:1
MQA@3"\U+"I+ (P="HA'FB.Q@"F.2B:3M:0^@2-HQ.AZ-[+:CA#)PWMB LO)6
M2H)R21GCQXG/UX"JCZAW2PVVW9VQU[V8@^U5+4*HU&DQTEH'U91,PE$S-4+7
M&'OZPFTGU;;B-CE*$M[BHB4;4SQN/MN6)X>&]R(<1N)QH2K:\-:1ND[W/C@=
M?+AX/K7W]1_IO;W=2?7^'ZZV)M+K+64.2.C',["5UYKQ9ASG,9U'%\H T ;C
M)/?#P7'X24T.;(K,9<@<GPR3-ZI6.2#:#"&D!&/##G=)\'=<O_;Q_K@N_:[Z
M\=8S7FGH)0R?9S1.T8W7$8:(1%+-LJBKU4623&&!"2TL1#\V12XHM&Y*M9FE
M,D1)EIRAN<' "4LY]<75>8I7GE!+"2<.&>. 1C.?#CT<%FV@>G"V0^_\[C[3
M7'(=O]NDK(HC$+L*51=G@E:4A%E85 %D>H*FV56[M, PO)5J4SM)7-_E<Q="
MCU@C7\D;P_9=2@NR-T##>>.9)\9_H*06Y58;&7/2LGJO7*T*MJ%ZL%CDT+F$
MVLJNI+9"EIB4HCKBR+%4&:F">09(@EZ8:W!Z!RD0I S$8!G)S&J'@/<4-(!R
M03X,''H*K1Z>?3FW_P"G)KP]ZV5CM5JU8L+ [OTJ@3E9.M]H^NHA)I0ZLJA[
M(5"BVP3$E?8J-*G?'!(UFDHW8F1.11PWX;0 37@JW/:\Y+2#XG#EQ_EX=7A4
MC>F?I5LUI*WW+%[FORI[\8;DMRR-AI#+&"I937MG.5SVFXQ]1*7)^<U5DRB*
M+HP)&SFE-[8@B[6Y(C1(R@NAC<D B"5+G!V, C  YYX#S#Q+D>JSI%<_4-UO
M==6(%:=2U17<]4,RVQY!.*QE5A3DE9#IC%)I$3*Z5LUBPQDCPAKX^J0R0]\:
M9$:N:%PT3=ZN&<>HR1C@T[V,D<N..8(X\"NK:X:Z]436^C:QH=)LSIK:K/4T
M09('&II86NMU)9JX1:,H"&F.))&;&MBT#0Y+VEH2I&L+L2WHU3@E2)SG,*MT
MRL<EI22PDG#AGJ!!'V#Y%W60[K[$$;PSG26&ZOU;(9!%]>D.SS#-W_:"0Q1N
MEM8N]CNM8-" #*CUFE1C)/5$A9'+TMB7.QL<1IBBC0S-4 X(PE&!N[V>O'+K
MP#X?&L-3GJHNC]KS6=S4;6[<U2;&_P#5NB>RE8W6H5$RZC)N^VPQUG9#*0FA
M"]8QRF2L1K\TN4>7DR=-'EC&]-\@.PJ4$J(P,IW..#_"7 CK&"0>/5YLJYCA
M4)PB<(G")PB<(G")PB<(L(;'6;8-.4M-[(JND9/L;/HR0S&QZF(:^LL:DDU-
M<I&SLRXIN>Y#@32APR-;BNDBP2@LTPY SJDR0DY:<G*&4@ G!./&LUDC&824
M882-.886 8R#!%C,(&(.!")&(D9A(AEBSD A%&&%Y$'.0#&'.!9*%^G"*"S%
MLQ9JWJ/S[3MWB\'25A'M0X7LA%Y<W+'U;.7ATE=J/=:*6E])4^A,3,A:U<2D
M)I*) E>3UZ94S.(WM&;E:RDE5CN0[KWB/D /I4Z>%2J6)$IF23KH6(HKYFC,
M@F9?1VKKU T3*2NL0C"Q6+=>R@#P[R-DB<X=6U.2F$>H")%%G4U2>24BR%(6
MI&O2QUCR'[0J_P#9C_.?^$**6V&GDDU.TPCJ)58K++;[V3ZQ.L>SMJ6 7$UB
M:!)+FM[9>O.Y+&(..1 =\U["T;/'6AO9U<K3.SZF:UBX]S9E+QDANE5!V\3X
M!&YH\@'VJ;,)M#<:K]X=@]2UEOL^SY;EI$W;5T"JN",0:ISHA9.;+E%6F5I*
M)'2L!:"%U9N[LC9GG+^IA[Y,F)ORH1!/>E"<:IQ*GN2 <8XX.,G(X<1D\^?B
M7":][&W._;^3C5DS:^(; QYTT<Q=SLZ,$3K-;':.V(9[7;JRD,:@CI7['%UK
M]79OKL;FGAMFOLPGK(8QID;Q-!'+U>.%! W0<8.<=?$8R#Q^T8'B4%8ULEU(
M3NCC8'4>>=S6%5,5FI\QDT8K]'K=6R5%%K#9;I<"\V(&4&+5!KLYK(&W+8BE
MC2J/%0YF/7(7HMD7JV<8'4J]UO;-W'[WA/+'+J4S9C+]Z:ZW/U!HE3MXAD<)
MW6I^^W.3^DT-6*)91<QHF,5W+5#[1!J5'A8J3RHJ:C9DK;>3A<B=@ D,=%6)
M$<<4C(*D!I:XXXM(QQ/'.>?R=6/,N:UIO?<*35[MY6$KN6KI--=5]YEM$/\
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%N?%?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
